FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766562100> ?p ?o ?g. }

• W2766562100 endingPage "97360" @default.
• W2766562100 startingPage "97344" @default.
• W2766562100 abstract "// Christian Bressy 1 , Dragomira Majhen 1 , Najat Raddi 1 , Wael Jdey 1 , Gaétan Cornilleau 1 , Léna Zig 1 , Josée Guirouilh-Barbat 2 , Bernard S. Lopez 2 , Olivia Bawa 3 , Paule Opolon 3 , Elodie Grellier 1 and Karim Benihoud 1 1 Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203 CNRS, Université Paris-Sud, Gustave Roussy, Université Paris-Saclay, Villejuif 94805, France 2 Laboratoire Recombinaison-Réparation et Cancer, UMR 8200 CNRS Stabilité Génétique et Oncogenèse, Université Paris-Sud, Gustave Roussy, Université Paris-Saclay, Villejuif 94805, France 3 Unité de pathologie expérimentale de l’IRCIV, Gustave Roussy, Villejuif 94805, France Correspondence to: Karim Benihoud, email: karim.benihoud@gustaveroussy.fr Keywords: colon; polyploidy; oncolytic adenovirus; DNA damage; HDACi Received: November 25, 2016     Accepted: August 04, 2017     Published: October 26, 2017 ABSTRACT The anti-tumor potential of oncolytic adenoviruses (CRAds) has been demonstrated in preclinical and clinical studies. While these agents failed to eradicate tumors when used as a monotherapy, they may be more effective if combined with conventional treatments such as radiotherapy or chemotherapy. This study seeks to evaluate the combination of a CRAd bearing a Δ24 deletion in E1A with valproic acid (VPA), a histone deacetylase inhibitor, for the treatment of human colon carcinomas. This combination led to a strong inhibition of cell growth both in vitro and in vivo compared to treatment with CRAd or VPA alone. This effect did not stem from a better CRAd replication and production in the presence of VPA. Inhibition of cell proliferation and cell death were induced by the combined treatment. Moreover, whereas cells treated only with CRAd displayed a polyploidy (> 4N population), this phenotype was increased in cells treated with both CRAd and VPA. In addition, the increase in polyploidy triggered by combined treatment with CRAd and VPA was associated with the enhancement of H2AX phosphorylation (γH2AX), a hallmark of DNA damage, but also with a decrease of several DNA repair proteins. Finally, viral replication (or E1A expression) was shown to play a key role in the observed effects since no enhancement of polyploidy nor increase in γH2AX were found following cell treatment with a replication-deficient Ad and VPA. Taken together, our results suggest that CRAd and VPA could be used in combination for the treatment of colon carcinomas." @default.
• W2766562100 created "2017-11-10" @default.
• W2766562100 creator A5002056766 @default.
• W2766562100 creator A5004835580 @default.
• W2766562100 creator A5007900554 @default.
• W2766562100 creator A5018470906 @default.
• W2766562100 creator A5028508500 @default.
• W2766562100 creator A5033410737 @default.
• W2766562100 creator A5035892485 @default.
• W2766562100 creator A5046397498 @default.
• W2766562100 creator A5049631545 @default.
• W2766562100 creator A5056220279 @default.
• W2766562100 creator A5067527518 @default.
• W2766562100 creator A5071702929 @default.
• W2766562100 date "2017-10-26" @default.
• W2766562100 modified "2023-10-10" @default.
• W2766562100 title "Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid" @default.
• W2766562100 cites W1491631791 @default.
• W2766562100 cites W1769808657 @default.
• W2766562100 cites W1808107661 @default.
• W2766562100 cites W1874618490 @default.
• W2766562100 cites W1969323007 @default.
• W2766562100 cites W1969858573 @default.
• W2766562100 cites W1974423981 @default.
• W2766562100 cites W1976046338 @default.
• W2766562100 cites W1983055880 @default.
• W2766562100 cites W1991660464 @default.
• W2766562100 cites W2005215585 @default.
• W2766562100 cites W2007952588 @default.
• W2766562100 cites W2009589033 @default.
• W2766562100 cites W2010969635 @default.
• W2766562100 cites W2011206688 @default.
• W2766562100 cites W2016724097 @default.
• W2766562100 cites W2018182154 @default.
• W2766562100 cites W2019083542 @default.
• W2766562100 cites W2023088570 @default.
• W2766562100 cites W2026677489 @default.
• W2766562100 cites W2028921845 @default.
• W2766562100 cites W2029770190 @default.
• W2766562100 cites W2031237979 @default.
• W2766562100 cites W2032428691 @default.
• W2766562100 cites W2034902271 @default.
• W2766562100 cites W2036045557 @default.
• W2766562100 cites W2037373653 @default.
• W2766562100 cites W2043645119 @default.
• W2766562100 cites W2064951429 @default.
• W2766562100 cites W2068751269 @default.
• W2766562100 cites W2070898966 @default.
• W2766562100 cites W2071888464 @default.
• W2766562100 cites W2073999186 @default.
• W2766562100 cites W2074494915 @default.
• W2766562100 cites W2090732350 @default.
• W2766562100 cites W2093048712 @default.
• W2766562100 cites W2096439168 @default.
• W2766562100 cites W2097018312 @default.
• W2766562100 cites W2098374956 @default.
• W2766562100 cites W2098435825 @default.
• W2766562100 cites W2106775330 @default.
• W2766562100 cites W2107190139 @default.
• W2766562100 cites W2110592777 @default.
• W2766562100 cites W2110962554 @default.
• W2766562100 cites W2121288523 @default.
• W2766562100 cites W2121836743 @default.
• W2766562100 cites W2123019823 @default.
• W2766562100 cites W2123677358 @default.
• W2766562100 cites W2124375652 @default.
• W2766562100 cites W2130567937 @default.
• W2766562100 cites W2135134946 @default.
• W2766562100 cites W2136870875 @default.
• W2766562100 cites W2137472906 @default.
• W2766562100 cites W2141433188 @default.
• W2766562100 cites W2146345889 @default.
• W2766562100 cites W2154214290 @default.
• W2766562100 cites W2156111187 @default.
• W2766562100 cites W2166838688 @default.
• W2766562100 cites W2168261379 @default.
• W2766562100 cites W2169503293 @default.
• W2766562100 cites W2318993502 @default.
• W2766562100 cites W4211199921 @default.
• W2766562100 doi "https://doi.org/10.18632/oncotarget.22107" @default.
• W2766562100 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5722567" @default.
• W2766562100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29228615" @default.
• W2766562100 hasPublicationYear "2017" @default.
• W2766562100 type Work @default.
• W2766562100 sameAs 2766562100 @default.
• W2766562100 citedByCount "9" @default.
• W2766562100 countsByYear W27665621002018 @default.
• W2766562100 countsByYear W27665621002020 @default.
• W2766562100 countsByYear W27665621002021 @default.
• W2766562100 countsByYear W27665621002022 @default.
• W2766562100 crossrefType "journal-article" @default.
• W2766562100 hasAuthorship W2766562100A5002056766 @default.
• W2766562100 hasAuthorship W2766562100A5004835580 @default.
• W2766562100 hasAuthorship W2766562100A5007900554 @default.
• W2766562100 hasAuthorship W2766562100A5018470906 @default.
• W2766562100 hasAuthorship W2766562100A5028508500 @default.
• W2766562100 hasAuthorship W2766562100A5033410737 @default.
• W2766562100 hasAuthorship W2766562100A5035892485 @default.

• next